Valuation: TScan Therapeutics, Inc.

Market Cap 58.72M 51.35M 47.39M 43.65M 82.32M 5.65B 84.13M 566M 222M 2.77B 221M 216M 9.53B P/E 2026 *
-1.05x
P/E 2027 * -0.99x
Enterprise Value -40.14M -35.1M -32.39M -29.84M -56.27M -3.86B -57.51M -387M -152M -1.89B -151M -147M -6.52B EV / Sales 2026 *
-5.31x
EV / Sales 2027 * -2.05x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-18 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-06 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+1.80%
1 week-13.70%
Current month-6.66%
1 month+7.86%
3 months-15.30%
6 months-19.04%
Current year-8.52%
1 week 0.88
Extreme 0.876
1.1
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Director of Finance/CFO 57 28/01/2024
Chief Tech/Sci/R&D Officer - 05/02/2024
Director TitleAgeSince
Chairman 55 11/06/2024
Director/Board Member 56 23/05/2023
Director/Board Member 68 05/04/2023
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Free

Director

67,000 0.1200%
20/05/26 Free

Director

67,000 0.1200%
20/05/26
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
+1.80%-13.70%-49.46%-56.64% 58.72M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -2.32%-2.65%+34.78%+166.65% 24.05B
Weighted average by Cap. -2.92%-2.20%+43.56%+156.98%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.1M 5.62M 10.59M 728M 10.83M 72.89M 28.63M 356M 28.38M 27.76M 1.23B 7.81M 6.83M 6.3M 5.8M 10.94M 752M 11.18M 75.3M 29.58M 368M 29.32M 28.67M 1.27B
Net income -115M -101M -92.85M -85.53M -161M -11.08B -165M -1.11B -436M -5.42B -432M -423M -18.68B -125M -109M -101M -92.78M -175M -12.02B -179M -1.2B -473M -5.88B -469M -458M -20.26B
Net Debt -98.87M -86.44M -79.78M -73.49M -139M -9.52B -142M -954M -375M -4.66B -371M -363M -16.05B -74.76M -65.36M -60.32M -55.57M -105M -7.2B -107M -721M -283M -3.52B -281M -275M -12.14B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
17/07/26 US$0.9148 +1.80% 143,873
16/07/26 US$0.8986 -2.65% 651,704
15/07/26 US$0.9231 -0.74% 473,755
14/07/26 US$0.9300 -9.71% 1,640,085
13/07/26 US$1.030 -5.50% 1,152,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9148USD
Average target price
6.000USD
Spread / Average Target
+555.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock